Cure My Disease

Don't miss your cure!

 Log in / Sign up

A protein clue may spot dialysis membrane failure before it starts

NCT ID NCT07806708

Diagnosis Sponsor: Universität des Saarlandes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

Peritoneal dialysis uses the belly lining as a natural filter for people with kidney failure, but over time this membrane can scar and stop working. This study tests whether levels of a protein called DKK3 in blood, urine, and dialysis fluid can serve as an early warning sign of that damage. Researchers will follow about 30 adults starting peritoneal dialysis for a year, measuring DKK3 and membrane function at several points. If DKK3 rises before membrane function declines, it could become a simple test to protect the dialysis treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Modified Peritoneal Equilibration Test and DKK3 biomarker measurement
What this could lead to
If DKK3 levels reliably signal early membrane scarring, doctors could detect problems before they cause treatment failure, potentially extending the usefulness of peritoneal dialysis.
What could go wrong
This is a small, exploratory study, so the results may not apply broadly. DKK3 might not prove to be a reliable early warning sign, and the test itself carries the usual risks of blood draws and dialysis fluid exchanges.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive adult patients with end-stage renal disease undergoing PD catheter insertion at the Department of Internal Medicine IV, Saarland University Medical Center, Homburg, Germany.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * End-stage renal disease with decision for peritoneal dialysis * PD catheter insertion at Department of Internal Medicine IV, Saarland University Medical Center * Written informed consent obtained at least 24 hours before the first study procedure Exclusion Criteria: * Age \<18 years * Lack of capacity to give informed consent * Pregnancy or breastfeeding * Active malignancy (except basal cell carcinoma of the skin) * Active peritonitis at time of inclusion * Life expectancy \<12 months as assessed by the treating physician * Severe peritoneal adhesions precluding PD catheter insertion (intraoperative assessment)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End stage renal disease (ESRD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease encapsulating peritoneal sclerosis end stage renal failure Peritoneal Fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End stage renal disease (ESRD) Peritoneal dialysis (PD) Peritoneal fibrosis Ultrafiltration failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Saarland University Medical Center

    Homburg, Saarland, 66421, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.